Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ascletis Raises Mammoth $100 Million To Deploy Its US-China Hybrid Model

This article was originally published in Start Up

Executive Summary

In the latest and most ambitious attempt to create a new global pharma with one foot in China and one in the West, Ascletis Inc. has launched with a hybrid drug development model that has attracted $100 million in committed funding.

You may also be interested in...



Morningside Group

Sequella TB Drug Deal Blurs The Line Between Licensing And Financing

For a small biotech seeking to out-license a promising asset in a far-flung territory, established pharmas typically make the best partners, given these big players have the infrastructure required to gain regulatory approval for a compound and bring it to market. But for Sequella Inc., a Rockville, MD-based infectious disease specialist, the commercial path of its tuberculosis drug in Russia and other former Soviet republics goes through a partner that will likely never sell the drug itself.

Sequella TB Drug Deal Blurs The Line Between Licensing And Financing

For a small biotech seeking to out-license a promising asset in a far-flung territory, established pharmas typically make the best partners, given these big players have the infrastructure required to gain regulatory approval for a compound and bring it to market. But for Sequella Inc., a Rockville, MD-based infectious disease specialist, the commercial path of its tuberculosis drug in Russia and other former Soviet republics goes through a partner that will likely never sell the drug itself.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel